- 2025 Financial Performance: Sales of EUR 45.5 billion and core earnings per share of EUR 4.91, aligning with guidance, with free cash flow of EUR 2.1 billion.
- Organizational Savings: Achieved EUR 2 billion in savings through the Dynamic Shared Ownership model, supporting operational efficiency.
- Litigation Provisions: Set aside EUR 11.8 billion for litigation-related liabilities, with 2026 expecting negative free cash flow due to payouts.
- Divisional Growth Projections: Crop Science (1-4% growth), Pharmaceuticals (50% growth for Nubeqa/Kerendia), and Consumer Health (0-4% growth) expected in 2026.
- Debt and Ratings: Net financial debt reduced below EUR 30 billion in 2025, targeting an A rating with leverage under 2.5; debt may rise in 2026 due to litigation.
Segment Performance
The company's divisions performed as follows: Crop Science progressed in its profitability improvement program, Pharmaceuticals had a rejuvenated picture with launch medicines driving growth, and Consumer Health maintained its bottom line despite market softness. Crop Science is focused on innovation, with a robust pipeline of crop protection products. Pharmaceuticals is expected to grow momentum for Nubeqa and Kerendia, with an expected growth of approximately 50% at constant currencies.
Litigation-Related Provisions and Liabilities
Bayer's litigation-related provisions and liabilities are based on a comprehensive assessment, with a provision of EUR 11.8 billion. The company expects a negative free cash flow in 2026 due to litigation-related payouts. CFO Wolfgang Nickl reported that the company's net financial debt was reduced below EUR 30 billion by the end of 2025.
Outlook for 2026
The company expects a solid performance in 2026, with product declines in Pharma and Crop Science offset by strong performance from launch products. Core earnings per share are expected to be roughly in line with last year. Analysts estimate next year's revenue growth at 2.7%. The company's guidance for 2026 includes net sales of EUR 45-47 billion, EBITDA before special items of EUR 9.6-10.1 billion, and core earnings per share of EUR 4.30-4.80.
Valuation Metrics
With a P/E Ratio of -185.57, P/B Ratio of 1.24, and EV/EBITDA of 11.55, the market seems to be pricing in the challenges Bayer is facing. The company's ROE is -0.64%, and Net Debt / EBITDA is 5.53, indicating a high level of debt. The Dividend Yield is 0.29%, and Free Cash Flow Yield is 10.72%. These metrics suggest that while the company is making progress in its turnaround plan, there are still challenges ahead.
Operational Efficiency
Bayer has reduced its workforce by around 14,000 jobs as part of its Dynamic Shared Ownership (DSO) program, aiming to increase efficiency and competitiveness. The company is focused on driving performance in its businesses rather than just reducing headcount.
Investment Plans
Bayer is making significant investments in Europe, including a new chemical research facility in Monheim and cell and gene therapy production in Berlin and San Sebastian. The company is also exploring opportunities in China, with five innovation hubs and over 100 collaborations with universities.